Low-cost Enabling Technology for Image-guided Photodynamic Therapy (PDT) of Oral

图像引导口腔光动力治疗 (PDT) 的低成本实现技术

基本信息

批准号：
9339767
负责人：
Jonathan P Celli
金额：
$ 98.98万
依托单位：
MASSACHUSETTS GENERAL HOSPITAL
依托单位国家：
美国
项目类别：
财政年份：
2014
资助国家：
美国
起止时间：
2014-09-19 至 2019-08-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/9339767
关键词：
Acacia Accounting Address Aminolevulinic Acid Area Asia Benchmarking Biological Models Biopsy Businesses Calibration Cancer Burden Cancer Etiology Cancer Patient Carcinogen exposure Caring Case Study Cellular Phone Cessation of life Charge Cheek structure Clinical Clinical Research Consultations Contrast Media Country Coupled Data Deglutition Dental Development Plans Devices Disease Early Intervention Economic Burden Education Engineering Fiber Goals Guidelines Hamsters Health Health Care Costs Health Services Accessibility Health Technology Healthcare Histology Hospitals Human Image Imaging technology Implant India International Lesion Light Location Magnetic Resonance Imaging Malignant Neoplasms Malignant neoplasm of cervix uteri Massachusetts Mastication Medical Modality Modeling Morbidity - disease rate Muslim population group Necrosis Nuts Operative Surgical Procedures Optical Instrument Optics Oral Oral cavity Output PUVA Photochemotherapy Pakistan Patients Performance Pharmacologic Substance Phase Physical Sufferings Physicians Population Provider Quality of life Radiation therapy Reporting Research Research Infrastructure Research Personnel Resources Rural Series Shapes Site Source Sri Lanka Staging Surgeon Technology The Sun Tobacco Trainers Training Training United States National Institutes of Health Universities Woman Work base cancer imaging cancer therapy clinical research site cost density design dimethylbenzanthracene engineering design experience fluorescence imaging follow-up forging global health image guided in vivo industry partner instrumentation low and middle-income countries malignant mouth neoplasm medical schools men mortality novel therapeutics oncology oral dysplasia oral lesion physical science pre-clinical research study rural area screening tissue phantom treatment response tumor validation studies

项目摘要

DESCRIPTION (provided by applicant): Oral cancer represents over 30% of cancers reported in India, one of the highest oral cancer rates in the world, (attributed to the widespread popularity of chewing "gutka") and is the leading cause of cancer death among Indian men. The overall impact is increased morbidity, mortality and economic burden. This application aims to address the problem of oral cancer by using a low cost adaptation of photodynamic therapy (PDT), an active area of research in our group. The thrust of the study is to design a platform that can be used at sites without medical infrastructure and uses battery-powered light sources and smart phones along with d-aminolevulinic acid, (ALA) as the photodynamic agent. We achieve this in four specific aims executed in two phases: We initially adapt and calibrate current clinical PDT technologies for LMIC use (Aims 1and 2 UH2 phase), then, conduct a validation study at the LMIC site (India) and establish a business plan for long term sustainability of low cost PDT as a global health technology for oral cancer treatment (Aims 3 and 4 UH3 phase).Aim 1 will adapt and calibrate existing PDT treatment and imaging technologies for oral cancers to a low-cost, battery powered format. Aim 2 will optimize LED-based ALA/PpIX PDT and Imaging in pre-clinical hamster models of oral cancer. Aim 3 will validate clinical performance of PDT treatment of oral cancers and dysplasia at LMIC sites. Aim 4 will establish a sustainable long-term business, dissemination and healthcare training plan. The design is made particular to the Indian context by strong collaborative relationships with surgeons and therapists in at the Jawaharlal Nehru Hospital, Aligarh Muslim University (AMU), India, DUSA pharmaceuticals, a subsidiary of Sun Pharmaceuticals (an India-based conglomerate and suppliers of ALA), Physical Sciences Inc. (PSI) an optical instrument design Massachusetts company and physician consultants with extensive experience in the delivery of PDT globally. The UH3 phase will also include a sustainable business plan development and will evaluate the long-term goal of incorporating solar powered batteries (not part of the current application) for which we will reach out for advice to the Dartmouth Humanitarian Engineering (DHE) that has devoted significant resources to studying sustainability issues in emerging economies. This will be facilitated by one of our investigators who is an active alumnus of DHE.

描述（由申请人提供）：口腔癌占印度报告的癌症的 30% 以上，印度是世界上口腔癌发病率最高的国家之一（归因于咀嚼“gutka”的广泛流行），并且是癌症死亡的主要原因在印度男性中。总体影响是发病率、死亡率和经济负担增加。该应用旨在通过使用低成本的光动力疗法（PDT）来解决口腔癌问题，这是我们小组的一个活跃研究领域。该研究的主旨是设计一个可以在没有医疗基础设施的场所使用的平台，并使用电池供电的光源和智能手机以及 d-氨基乙酰丙酸 (ALA) 作为光动力剂。我们通过分两个阶段执行的四个具体目标来实现这一目标：我们首先调整和校准当前临床 PDT 技术以供 LMIC 使用（目标 1 和 2 UH2 阶段），然后在 LMIC 站点（印度）进行验证研究并制定业务计划实现低成本 PDT 作为口腔癌治疗全球卫生技术的长期可持续性（目标 3 和 4 UH3 阶段）。目标 1 将调整和校准现有的口腔癌 PDT 治疗和成像技术到低成本、电池供电的格式。目标 2 将优化口腔癌临床前仓鼠模型中基于 LED 的 ALA/PpIX PDT 和成像。目标 3 将验证 PDT 治疗中低收入国家 (LMIC) 部位口腔癌和不典型增生的临床效果。目标 4 将建立可持续的长期业务、传播和医疗保健培训计划。该设计专门针对印度环境而设计，与印度阿里格尔穆斯林大学 (AMU) 贾瓦哈拉尔尼赫鲁医院的外科医生和治疗师、太阳制药公司（一家印度企业集团和药品供应商）的子公司 DUSA 制药公司建立了密切的合作关系。 ALA)、Physical Sciences Inc. (PSI) 是一家马萨诸塞州光学仪器设计公司和医生顾问，在全球提供 PDT 方面拥有丰富的经验。 UH3 阶段还将包括可持续商业计划的制定，并将评估纳入太阳能电池（不是当前应用的一部分）的长期目标，为此我们将向达特茅斯人道主义工程 (DHE) 寻求建议，该工程已投入大量资源来研究新兴经济体的可持续性问题。我们的一位研究人员是 DHE 的活跃校友，将协助这一工作。